Key facts
- This page summarizes Augustine Lawlor's Form 4 filing for LEAP THERAPEUTICS, INC. (LPTX).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 01 Jul 2025, 16:30.
Augustine Lawlor - 30 Jun 2025 Form 4 Insider Report for LEAP THERAPEUTICS, INC. (LPTX)
- Reporting relationship
- Chief Operating Officer
- Issuer ticker
- LPTX
- Reported as of
- 30 Jun 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 01 Jul 2025, 16:30:53 UTC
- Prior SEC filing
- 01 Apr 2025
- Next SEC filing
- 18 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Douglas E. Onsi, as attorney-in-fact for Augustine Lawlor
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Augustine Lawlor filed Form 4 for LEAP THERAPEUTICS, INC. (LPTX) on 01 Jul 2025.
Change
- Previous filing in this sequence was filed on 01 Apr 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001262327
Primary reporting owner
LAWLOR AUGUSTINE
- Relationship
- Chief Operating Officer
- Address
- C/O LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE
- Signature
- /s/ Douglas E. Onsi, as attorney-in-fact for Augustine Lawlor
- Signature date
- 01 Jul 2025
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Augustine Lawlor is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
SEC remarks
The reporting person is no longer serving as the Chief Operating Officer of Leap Therapeutics, Inc., effective June 30, 2025. As a result, the reporting person is no longer subject to Section 16 in connection with his transactions in the equity securities of Leap Therapeutics, Inc. and therefore will no longer report any such transactions on Form 4 or Form 5.